Lithium Ion

Lithium Ion

SCHEMBL6636809

O=[S-](=O)c1ccc2oc(-c3ccncc3)cc2c1.[Li+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3B known ✓ P49841 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
QPCT Q16769 1/20 0.40
HIF1A Q16665 1/20 0.40
MAOB P27338 3/20 0.40
APP P05067 4/20 0.38
FFAR1 O14842 2/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CFTR P13569 1/20 0.36
CYP1B1 Q16678 1/20 0.36
CYP19A1 P11511 1/20 0.36
CDC7 O00311 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10902022 0.74 RAB9A (0.50) ESR1ESR2GSK3BHIF1AMAOB
SCHEMBL10901534 0.74 MAOB (0.70) ESR1ESR2HIF1AMAOBAPP
SCHEMBL6636523 0.74 ADRA2A (0.59) ESR1ESR2MAOBCYP19A1ADRA2A
SCHEMBL10899785 0.74 MAPK14 (0.49) ESR1ESR2GSK3BQPCTHIF1A
Pyridarone SCHEMBL2109298 0.72 MAOB (0.62) MAOBCYP1A1CYP1A2POLBCFTR
Pyridarone SCHEMBL29993452 0.72 MAOB (0.62) MAOBCYP1A1CYP1A2POLBCFTR
SCHEMBL6809812 0.72 CA1 (0.44) ESR1ESR2GSK3BQPCTHIF1A
SCHEMBL10901776 0.71 FFAR1 (0.52) ESR1ESR2GSK3BHIF1AMAOB
SCHEMBL14840839 0.71 HIF1A (0.49) ESR1ESR2GSK3BQPCTHIF1A
SCHEMBL10901627 0.71 APP (0.68) MAOBAPPADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1217002-B1 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors SERVIER LAB (FR) 2004-09-22 EP disclosed
US-6686348-B2 N-HYDROXY-6-((2-(4-PYRIDYL)-1-BENZOFURAN-5-YL)SULPHONYL)-4,5,6,7 -TETRAHYDRO(2,3-C)-PYRIDINE-5-CARBOXAMIDE FOR EXAMPLE; TREATING RHEUMATIC DISEASES, CANCER LES LABORATOIRES SERVIER (FR) 2004-02-03 US disclosed
US-20020137744-A1 Metalloprotease inhibitors LES LABORATOIRES SERVIER (FR) 2002-09-26 US disclosed
EP-1217002-A1 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors Les Laboratoires Servier (FR) 2002-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137744-A1 Metalloprotease inhibitors MMP9, MMP3, MMP2 GSK3B 2771/4885ESR1 1878/4885ESR2 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.